Suchergebnisse

What does Europe's new Copyright Directive mean for your library? In this webinar, LIBER's Copyright & Legal Matters working group reviews the key points of the Directive, expanding on the points in this blog post. The implementation of the Copyright Directive on a national level is also discussed. This is critical because all European Directives set high-level goals, and allow much flexibility and leeway in exactly how those aims are achieved. Depending on what your national government decides, new activities and services for your library could be opened up or a situation could be created where the costs, overheads or rules associated with implementation mean that, in effect, the new copyright laws cannot be enjoyed at all. LIBER is willing to support its libraries in helping with national implementation, to ensure that our sector gets the best result possible. In this webinar, we discuss how you can engage proactively in implementation. Our speakers are Ben White (British Library), Armin Talke (Legal Advisor, Berlin State Library) and Jonas Holm (Senior Associate, MarLaw AB Law Firm). The webinar is hosted by Giannis Tsakonas (LIBER Executive Board member; Acting Director in the Library & Information Center, University of Patras). A recording of the webinar can be found here.

Aims Patients with advanced heart failure (AdHF) who are ineligible for heart transplantation (HTx) can become candidates for treatment with a left ventricular assist device (LVAD) in some countries, but not others. This reflects the lack of a systematic analysis of the usefulness of LVAD systems in this context, and of their benefits, limitations and cost-effectiveness. The SWEdish evaluation of left Ventricular Assist Device (SweVAD) study is a Phase IV, prospective, 1:1 randomized, non-blinded, multicentre trial that will examine the impact of assignment to mechanical circulatory support with guideline-directed LVAD destination therapy (GD-LVAD-DT) using the HeartMate 3 (HM3) continuous flow pump vs. guideline-directed medical therapy (GDMT) on survival in a population of AdHF patients ineligible for HTx. Methods A total of 80 patients will be recruited to SweVAD at the seven university hospitals in Sweden. The study population will comprise patients with AdHF (New York Heart Association class IIIB-IV, INTERMACS profile 2-6) who display signs of poor prognosis despite GDMT and who are not considered eligible for HTx. Participants will be followed for 2 years or until death occurs. Other endpoints will be determined by blinded adjudication. Patients who remain on study-assigned interventions beyond 2 years will be asked to continue follow-up for outcomes and adverse events for up to 5 years. Conclusion The SweVAD study will compare survival, medium-term benefits, costs and potential hazards between GD-LVAD-DT and GDMT and will provide a valuable reference point to guide destination therapy strategies for patients with AdHF ineligible for HTx. ; Funding Agencies|Sahlgrenska University Hospital; Swedish Research CouncilSwedish Research Council; Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation; Swedish Federal Government under the ALF agreement [ALFGBG-775351, 447561, 726481]